JAK2 and diffuse large B-cell lymphoma: This observation suggests that luteolin may modulate the JAK2/STAT3 signaling pathway by inhibiting the phosphorylation of JAK2 and STAT3, which could be a key mechanism underlying its antitumor effects in DLBCL.